KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Multiple Sclerosis, Primary Progressive

Conditions

Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS

Trial Timeline

Sep 20, 2024 → Jan 1, 2029

NCT ID

NCT06384976

About KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB

KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB is a phase 2 stage product being developed by Kyverna Therapeutics for Multiple Sclerosis, Primary Progressive. The current trial status is active. This product is registered under clinical trial identifier NCT06384976. Target conditions include Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Sclerosis, Primary Progressive were approved

Approved (20) Terminated (0) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved

✅TeclistamabJohnson & JohnsonApproved

✅BortezomibJohnson & JohnsonApproved

✅DaratumumabJohnson & JohnsonApproved

✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06384976	Phase 2	Active	Sep 20, 2024	Jan 1, 2029	Multiple Sclerosis, Primary Progressive

Competing Products

20 competing products in Multiple Sclerosis, Primary Progressive

See all competitors

Product	Company	Stage	Hype Score
mRNA-1195	Moderna	Phase 2	0
NEX-20A	Nanexa AB	Phase 1	23
mRNA-2736	Moderna	Phase 1	0
mRNA-2808	Moderna	Phase 2	0
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
Duloxetine Hydrochloride (HCI) + Placebo	Eli Lilly	Phase 3	40
Temferon	Genenta Science	Phase 1/2	14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
CS-0777 tablets + CS-0777 tablets + CS-0777 tablets	Daiichi Sankyo	Phase 1	29
ASP7487, Velcade, Dexamethasone	Astellas Pharma	Phase 1/2	24
PHE885	Novartis	Phase 2	27
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo	Astellas Pharma	Approved	43
Denileukin Diftitox (Ontak)	Eisai	Phase 1	21
Palonosetron	Eisai	Phase 2	35
BIW-8962	Kyowa Kirin	Phase 1	21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)	Kyowa Kirin	Phase 2	35